The NC Precision Health Collaborative is partnering with Color to empower employers to personalize employee health with genetic insights.

The North Carolina Biotechnology Center and Color are seeking employers to participate in the CHAMPPS pilot: Cancer & Hereditary disease Management & Pharmacogenomics - Population Screening. Through this pilot, participating employees will discover what their genes say about their health, such as their risk for common hereditary cancers and heart conditions and how their genes impact how the body may process certain medications.

Employers have the opportunity to personalize employee health

- Genetics significantly impact our health. CHAMPPS can supplement your other fitness, nutrition, prevention and wellness initiatives.
- Access to genetic information empowers employees to work with their healthcare provider to personalize their screening plan.

Understanding risk helps save lives, lower treatment costs, and promote wellness

- Early knowledge of our genetic risk helps detect disease at an earlier, more treatable stage, if not prevent it entirely.
- Understanding how our genes influence how our bodies may process certain medications may help improve adherence and outcomes, and reduce costs.

CHAMPPS couples genetic insights with the human touch to personalize health

- Assessments of one’s personal health risk powered by genetic data, personal and family health history, and more.
- Ongoing complimentary access to genetic counselors and clinical pharmacists.
- Consumer-friendly tools and services to manage test results, receive updates, etc.

Implementing CHAMPPS is fast and easy for employers

- We work with you to create a communications and education plan for all employees.
- We take care of providing custom support, confidential employee workflows, educational seminars, training, and more.

NC Precision Health Collaborative

Color for Employers

“Visa offers Color because it’s a perfect fit with our preventive health strategy. Our employees love it, and we’ve seen exceptionally strong utilization.”

Vice President of Global Benefits, Visa

“We want to empower our employees to treat disease before they get it...if you can put a program like Color’s in place and get people to participate, you’ll see ROI.”

Head of North America Total Rewards, SAP
CHAMPPS Pilot: Cancer & Hereditary Disease Management & Pharmacogenomics - Population Screening

CHAMPPS is a pilot project to gather evidence about the benefits and harms of population screening of healthy adults. In addition to informing participants about their risk for certain hereditary cancers and heart disease, and genes that may influence medication response, findings from the CHAMPPS project will inform health care and public health systems, and health insurance companies and public payers (i.e., Medicare and Medicaid) about how population screening for hereditary risk and pharmacogenomics may improve health outcomes and prove cost-effective. This project also serves as an educational opportunity for business leaders and the North Carolina workforce about the possible role of public health genomics today and into the future.

The Centers for Disease Control (CDC) has recognized the significant public health impact of identifying people with Tier 1 genomic conditions: Hereditary Breast and Ovarian Cancer, Lynch Syndrome, and Familial Hypercholesterolemia. It is estimated that nearly 2-3 million people are at increased risk for adverse health outcomes because they have genetic mutations which predispose them to these conditions, and yet up to 90% of affected individuals are unaware of their risk. These conditions are highly actionable meaning that evidence-based guidelines and health recommendations exist for early detection and intervention that could significantly reduce morbidity and mortality.

Pharmacogenomic screening of healthy individuals may provide useful genetic information that healthcare providers can consider, along with other information like an individual's health history, body size, and other medications they are taking, when selecting a medication or determining appropriate dosage. With CHAMPPS, we hope to identify asymptomatic adults who stand to benefit from established preventive modalities or medication changes if their risks were known.

What will participating employees learn?

Cancer
The BRCA+Lynch Test analyzes 7 genes, including BRCA1 and BRCA2, in which a mutation can increase one's likelihood of developing hereditary breast, ovarian, colorectal, uterine, prostate, or other cancers. The results can help the participant and their doctor create a personalized plan which increases the chance of prevention and early detection.

Heart
The Hereditary High Cholesterol Test analyzes 3 genes commonly associated with familial hypercholesterolemia, a genetic condition that increases one's chance of developing early heart disease. Knowing one's risk can help them and their doctor create a plan that goes beyond routine cholesterol management.

Medications
The Medication Response Genetic Test analyzes 14 genes that can influence how the body processes certain medications.